Latest Breaking News On - Dashyant dhanak - Page 1 : vimarsana.com

Deciphera Pharmaceuticals, Inc Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Deciphera Pharmaceuticals, Inc Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomHong kongNew zealandMaghan meyersDashyant dhanakDavid rosenEuropean unionDeciphera pharmaceuticalsCompensation committee of deciphera board directorsDeciphera pharmaceuticals incExecutive vice presidentChief scientific officerCompensation committeeNasdaq listing rule

Deciphera Pharmaceuticals, Inc Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

15.09.2023 - Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that in connection with the .

United kingdomHong kongNew zealandUnited statesDashyant dhanakDeciphera pharmaceuticalsDeciphera pharmaceuticals incEuropean unionDeciphera pharmaceuticals stockCompensation committee of deciphera board directorsExecutive vice presidentChief scientific officerCompensation committeeNasdaq listing rule

Deciphera Pharmaceuticals, Inc Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Deciphera Pharmaceuticals, Inc. , a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today.

Hong kongUnited statesUnited kingdomNew zealandDashyant dhanakCompensation committee of deciphera board directorsDeciphera pharmaceuticals incDeciphera pharmaceuticalsEuropean unionExecutive vice presidentChief scientific officerCompensation committeeNasdaq listing rule

Deciphera Pharmaceuticals Announces Second Quarter 2023 Financial Results

– Second Quarter 2023 Total Revenue of $38.3 Million; Net Product Revenue for QINLOCK® (ripretinib) Increased 18% to $37.3 Million Compared to Second Quarter 2022 –– Top-line Results for MOTION Pivotal Phase 3 Study of Vimseltinib Expected in Fourth Quarter 2023 –– INSIGHT Pivotal Phase 3 Study of QINLOCK in Second-.

New zealandUnited statesUnited kingdomHong kongDaniell flynnDan flynnJamesa bristolMaghan meyersSteve hoerterDashyant dhanakDavid rosenPfizer incDeciphera pharmaceuticals incResearch engineExchange commissionDeciphera pharmaceuticals

Deciphera Pharmaceuticals Announces Retirement of Daniel L Flynn, Ph D , and Appointment of Dashyan

Deciphera Pharmaceuticals Announces Retirement of Daniel L Flynn, Ph D , and Appointment of Dashyan
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.

United kingdomNew zealandUnited statesHong kongMaghan meyersJim bristolSteve hoerterJamesa bristolDashyant dhanakDaniell flynnDavid rosenChairperson or coCompany founderPfizer incDeciphera pharmaceuticalsUniversity of london